CompletedNCT06319170
This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- United States
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Condition
- Schizophrenia
TerminatedNCT03900754
This study exists to understand what helps a digital app or remote support tool work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 70 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
CompletedNCT07305779
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Schizophrenia
CompletedNCT06315283
This study exists to see whether the medication TV-44749 can play a useful role in care. Researchers are trying to understand how people respond to the medication TV-44749 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- Croatia, Spain, United Kingdom, United States
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Condition
- Schizophrenia
CompletedNCT07326618
This study exists to understand what helps a digital app or remote support tool work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Turkey
- Sponsor
- Dokuz Eylul University
- Condition
- Schizophrenia
CompletedNCT05660018
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT06993831
This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 70 Years
- Countries
- Denmark
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
- Condition
- Schizophrenia
CompletedNCT01626885
This study exists to understand how the medication MP-214 holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 20 Years to 64 Years
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT01626872
This study exists to understand how the medication MP-214 holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 20 Years to 65 Years
- Countries
- Japan, South Korea, Taiwan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT01625897
This study exists to understand how the medication MP-214 holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 20 Years to 74 Years
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT00862992
This study exists to understand whether the medication MP-214 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication MP-214 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 20 Years to 65 Years
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT01625000
This study exists to understand whether the medication MP-214 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 20 Years to 64 Years
- Countries
- Japan, South Korea, Taiwan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT01626859
This study exists to understand whether the medication MP-214 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 20 Years to 64 Years
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT04681807
This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 15 Years to 35 Years
- Countries
- Canada
- Sponsor
- The Royal Ottawa Mental Health Centre
- Condition
- Schizophrenia
CompletedNCT04115319
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Romania, Russian Federation, Ukraine, United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Schizophrenia
TerminatedNCT04986072
This study exists to see whether blood tests and biological markers can make care clearer and more responsive. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 40 Years
- Countries
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
- Condition
- Schizophrenia
CompletedNCT07310615
This study exists to see whether psychoeducation, a guided learning and support program, can make care clearer and more responsive. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Turkey
- Sponsor
- Ömer USLU
- Condition
- Schizophrenia
CompletedNCT01373866
This study exists to understand what helps brain scans or other body measurements work in everyday practice, not just under ideal conditions. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 13 Years to 60 Years
- Countries
- France
- Sponsor
- University Hospital, Lille
- Condition
- Schizophrenia
CompletedNCT02150174
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- France
- Sponsor
- University Hospital, Strasbourg, France
- Condition
- Schizophrenia
CompletedNCT04517279
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can work better when mental health difficulties overlap with substance use.
SchizophreniaOtherFrom 15 Years to 32 Years
- Countries
- United States
- Sponsor
- University of Texas at Austin
- Condition
- Schizophrenia
CompletedNCT02570594
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- France
- Sponsor
- University Hospital, Strasbourg, France
- Condition
- Schizophrenia
CompletedNCT02744989
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- France, Monaco
- Sponsor
- Hospices Civils de Lyon
- Condition
- Schizophrenia
CompletedNCT06608498
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherFrom 18 Years to 30 Years
- Countries
- United States
- Sponsor
- University of Washington
- Condition
- Schizophrenia
CompletedNCT06389266
This study exists to compare options and see whether smoking support or smoking-related treatment offers something meaningfully different. Researchers are trying to understand whether smoking support or smoking-related treatment can better support energy, concentration, and everyday functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Vanderbilt University Medical Center
- Condition
- Schizophrenia
CompletedNCT05919823
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- China
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia